A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone
Status:
Unknown status
Trial end date:
2019-12-30
Target enrollment:
Participant gender:
Summary
The A-One study is a prospective, randomized controlled trial evaluating the use of the One
Drop | Premium 'On Track' in combination with Afrezza treatment on the glycemic control,
treatment adherence, social-cognitive barriers to adherence, and treatment satisfaction of
people with Type 2 diabetes (T2D) and a hemoglobin A1c (A1c) > 7.0% already prescribed an
injectable rapid-acting insulin.